Love this! #philsky #academicsky

Over the last decade, proteomics analysis of single cells by mass spectrometry transitioned from an uncertain possibility to a set of robust and rapidly advancing technologies supporting the accurate ...

If you’re using 10x Genomics (Flex v1) for scRNA-seq, this study is a must-read. 🧪 It uncovers a key artefact: • Probe barcodes themselves introduce bias • Some barcodes systematically alter gene expression signals • Apparent DEGs may be technical, not biological https://www.biorxiv.org/content/10.64898/2026.04.06.716804v1

We wrote two reviews on cell migration, published today in Nature Methods. They provides practical guidelines how to select a cell-migration assay and how to analyze cell-migration data Review 1: https://nature.com/articles/s41592-025-02935-5 Review 2: https://nature.com/articles/s41592-025-02890-1

YouTube video by CellMorphoJSero

In this Review, Isbel et al. describe our current understanding of how transcription factors navigate features of chromatin — particularly DNA methylation and nucleosomes — and how this contributes to...

The CD47/SIRPα axis conveys a ‘don’t eat me’ signal, thereby thwarting the phagocytic clearance of tumor cells. Although blocking antibodies targeting CD47 have demonstrated promising anti-tumor effects in preclinical models, clinical trials involving human cancer patients have not yielded ideal results. Exploring the regulatory mechanisms of CD47 is imperative for devising more efficacious combinational therapies. Here, we report that inhibiting USP2 prompts CD47 degradation and reshapes the tumor microenvironment (TME), thereby enhancing anti-PD-1 immunotherapy. Mechanistically, USP2 interacts with CD47, stabilizing it through deubiquitination. USP2 inhibition destabilizes CD47, thereby boosting macrophage phagocytosis. Single-cell RNA sequencing shows USP2 inhibition reprograms TME, evidenced by increasing M1 macrophages and CD8+ T cells while reducing M2 macrophages. Combining ML364 with anti-PD-1 reduces tumor burden in mouse models. Clinically, low USP2 expression predicts a bett